Quick Facts

• Management of airflow obstruction
• Long-term maintenance treatment for chronic respiratory conditions
• Improved lung function
• Reduction of exacerbations in chronic obstructive pulmonary disease (COPD) and asthma

Respiro: Therapeutic Overview

Respiro is indicated for the maintenance treatment of chronic respiratory conditions where airflow obstruction is a primary factor. The drug's main purpose is to support sustained respiratory function in adults diagnosed with conditions like chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and emphysema, and asthma.

The therapeutic action provides improved lung function and helps patients manage symptoms of breathlessness and wheezing. A key benefit of its use is the reduction in the frequency of exacerbations (acute worsening of symptoms), leading to enhanced daily activity and overall status in patients with these long-term obstructive pulmonary diseases. Treatment is often guided by assessing its effect on pulmonary function measures such as FEV1 (Forced Expiratory Volume in one second).

Regulatory References

1. NIH MedlinePlus guidance

Who Can and Cannot Use Respiro?

This section outlines the officially documented population eligibility rules for Respiro (Fluticasone Propionate/Salmeterol) as defined by governmental regulatory authorities.

Contraindicated Populations (Absolute Non-Eligibility)

Respiro must not be used for the primary treatment of status asthmaticus or other acute episodes of asthma or COPD, as it is a maintenance drug, not a rescue inhaler. It is also contraindicated in patients with a known severe hypersensitivity to Fluticasone Propionate, Salmeterol, or any of its excipients, including a severe milk protein allergy (for powder formulations).

Age and Comorbidity Restrictions

Respiro is approved for the long-term maintenance of asthma in adults and adolescents (12 years of age and older) and in children 4 years and older (specific to formulation). Safety and effectiveness are not established in children younger than 4 years. Caution is required for patients with hepatic impairment (liver disease), as the components are metabolized in the liver, necessitating close monitoring. Use also requires caution in patients with pre-existing cardiovascular disorders (such as arrhythmias or hypertension) and systemic infections.

Pregnancy and Lactation

Use during pregnancy is permitted only if the potential benefit justifies the potential risk, as human data are limited. For lactation, the decision to use the drug or discontinue breastfeeding must be made based on the drug’s importance to the mother.

Interactions with other medicines and products

Official regulatory information for Respiro (Fluticasone Propionate/Salmeterol) identifies specific interactions categorized by their effect and the resulting restrictions on co-administration.

Formally Documented Interaction Constraints

Pharmacodynamic and Cautionary Interactions

Specific caution is advised by regulatory authorities when Respiro is co-administered with certain medications due to the potential for potentiated effects:

• beta-Adrenergic Receptor Blocking Agents: Use with caution, as they may block the bronchodilatory effects of the Salmeterol component.
• Monoamine Oxidase Inhibitors (MAOIs) and Tricyclic Antidepressants (TCAs): Use with extreme caution, as these may potentiate the Salmeterol component’s effect on the vascular system.
• Non-Potassium-Sparing Diuretics: Caution is advised, as the hypokalemic effect associated with these diuretics may be worsened by the Salmeterol component.

For patients with severe hepatic impairment, regulatory documents note that caution is required due to potential reduced clearance of both active ingredients, which may increase systemic exposure.

Respiro functions as a highly selective dual antagonist of the P2X3 receptor and the P2X2/3 receptor heteromer, primarily located on sensory C-fibers within the airway epithelium. The P2X receptors are ligand-gated ion channels activated by extracellular adenosine triphosphate (ATP), which serves as a potent signaling molecule released during cellular stress or mechanical stimulation. By binding to the ATP-binding sites of these receptors, Respiro prevents ATP from triggering channel opening. This blockade inhibits the resultant rapid influx of cations, which in turn suppresses the afferent nerve fiber depolarization and subsequent generation of action potentials. The suppression of signaling at the peripheral level modulates the brainstem respiratory center input. This specific receptor antagonism interrupts the reflex arc, thereby decreasing the frequency and intensity of signals originating from the airways and ascending to the central nervous system.

Respiro (Fluticasone Propionate/Salmeterol) is used as a scheduled, long-term maintenance therapy for chronic respiratory conditions. The route of administration is oral inhalation, delivered directly to the lungs using either a dry powder inhaler (DPI) or a pressurized metered-dose inhaler (MDI).

The medicine is administered on a fixed twice-daily schedule, with doses taken approximately 12 hours apart, and is not for the relief of acute symptoms. If a dose is missed, the general practice is to skip the missed dose and take the next scheduled dose; the dose is not to be doubled. Respiro is used in adults and in pediatric patients ≥ 4 years for asthma, with specific dose strengths applying to younger children.

The specific strength and regimen depend on the indication:

The procedure for use involves specific steps. Following each use, the mouth is rinsed with water and the water is spit out to manage residue from the inhaled medicine. Furthermore, MDI devices typically require priming before first use or after periods of non-use, while DPI formulations are designed for use without a spacer. Once control is achieved, the dose is typically lowered to the minimum strength necessary to maintain symptom control.

Respiro: Recent Clinical Evidence

Core Research Findings

Research has focused on studies evaluating Respiro's effects in adult patients. Studies in this area often explore the drug's interaction with specific neurotransmitter pathways.

A recent study reported the results of a 12-week randomized trial. Studies investigated whether the drug was associated with changes in symptoms over time, compared to a placebo. This trial included participants with a confirmed diagnosis who had not responded adequately to prior treatments.

Studies on Combination Use

Studies explored whether the combination of this drug with an established standard-of-care medication was associated with changes in quality of life measures.

Research has investigated potential interactions when combining the drug with common pain relievers. The preliminary report indicated an observation that a subset of participants receiving the combination therapy reported fewer instances of treatment interruption compared to those receiving the drug alone.

Comparative and Long-Term Data

Research has compared outcomes of this treatment with older therapies in a non-randomized, observational study. Results showed that the group receiving the newer treatment had a different profile of reported side effects. Observations from the study did not establish a clinical advantage based on these differences.

Studies included patients with mild liver impairment. Research on the drug's effects in individuals with severe kidney or heart conditions was not a primary focus of the reviewed studies.

Long-term surveillance studies, extending beyond 24 weeks, continued to monitor participants. Researchers evaluated findings across key measurement scales for the condition over this extended period.

Key Studies & References A Randomized, Double-Blind, Chronic Dosing (24 Weeks), Placebo-Controlled, Parallel Group, Multi-Center Study to Assess the Effi - ClinicalTrials.gov (NCT02343458)

Common questions about Respiro (FAQ)

Q: Can I use Respiro with a spacer?

Regulatory instructions on device use vary by formulation. For the Dry Powder Inhaler (DPI) formulation, official product information indicates the device is not intended for use with a spacer or volume holding chamber. For the Metered Dose Inhaler (MDI) formulation, patients are directed to consult the regulatory instructions provided with their specific device for proper guidance on spacer use.

Q: Is Respiro safe for use during pregnancy?

According to official regulatory documents, the use of this medicine during pregnancy is permitted only if the potential benefit to the patient is considered to justify the potential risk to the fetus, as human safety data are limited. The regulatory documents note that pregnant patients with asthma should be closely monitored to maintain optimal asthma control.

Q: Why do I need to rinse and spit after using the inhaler?

Official product information includes the instruction to rinse the mouth with water and then spit it out after each use of the inhaler. This required step helps to reduce the amount of medicine residue left in the mouth and throat. Managing this residue helps to reduce the risk of localized infections, specifically oral candidiasis, commonly known as thrush.

Q: Can patients with liver disease use Respiro?

Regulatory documents indicate that caution is required when this medicine is used by patients with hepatic impairment (liver disease). The components of Respiro are metabolized in the liver, meaning liver impairment could potentially lead to reduced clearance and increased systemic exposure. Regulatory documents suggest close monitoring may be necessary for these patients during treatment.

Q: How do I know when the inhaler is empty?

The Dry Powder Inhaler (DPI) device is equipped with a dose counter. This counter displays the number of doses remaining in the device. Official instructions specify that the device is to be discarded once the dose counter reaches '0'.

Q: Do I have to prime the inhaler before every use?

For the Metered Dose Inhaler (MDI) formulation, priming is generally not required before every use. The official instructions specify that priming the device is required before first use, or if it has not been used for a specific duration (such as more than 4 weeks), or if it has been dropped.

Q: Can I get this medicine in a tablet form?

No, official regulatory documents list the approved dosage forms as an inhalation powder or a pressurized metered-dose inhalation aerosol. A tablet form is not approved or listed as an available dosage form for this medicine.

Q: Is Respiro a corticosteroid?

Respiro is a fixed-dose combination product that contains two different types of medicines. One active ingredient, Fluticasone Propionate, is an Inhaled Corticosteroid (ICS). The second ingredient, Salmeterol, is a Long-Acting Beta-2 Agonist (LABA).

Q: Is there a generic version of Respiro available?

Yes, according to official regulatory databases that track approved drugs, the combination of Fluticasone Propionate and Salmeterol Inhalation Powder is available as a generic drug product.

How to Store and Dispose of Respiro?

This section outlines the storage and disposal requirements for Respiro as officially documented in regulatory labeling.

Storage Requirements

Respiro must be stored at a controlled room temperature, typically between 20°C and 25°C (68°F and 77°F). The product must be protected from both moisture and light. It is a mandatory requirement to keep the medication out of the sight and reach of children. The product must not be exposed to freezing temperatures or excessive heat.

Handling and Stability

Storage rules require that the device be kept in its original packaging prior to first use and that the inhaler be properly closed afterward. The product is subject to an in-use stability period, requiring that the device be discarded a specific time after the foil pouch is opened, regardless of whether all doses have been used.

Disposal Instructions

Unused or expired Respiro must be disposed of according to local regulations, often through a community take-back program. The aerosol canister must not be punctured, thrown into fire, or incinerated, even when empty, due to its pressurized contents.